×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Sapiens to be Acquired by Advent for $2.5 Billion

  • August 13, 2025

Advent - Sapiens Merger

Sapiens International Corporation N.V. (SPNS) entered a merger agreement on August 13, 2025, to be acquired by Advent in an all-cash deal valued at $2.5 billion.

Deal Structure:

Sapiens shareholders will receive $43.50 per common share in cash, representing a 47.46% premium over the stock’s last close.

Company Profile:

Sapiens is a global provider of intelligent SaaS-based software solutions for the insurance and financial services industries, offering AI-driven platforms that support core, digital, reinsurance, compliance, and decision management needs for over 600 customers in more than 30 countries.

Advent is a private equity firm that partners with management teams to transform businesses, overseeing about $94 billion in assets under management.

Deal Details and Timeline:

Formula Systems (1985) Ltd., an existing Sapiens shareholder, will retain a minority stake in the company.

Advent has secured committed debt and equity financing to fund the transaction. Funds advised by Advent have agreed to invest a total of $1.3 billion in equity.

The deal is expected to close in the fourth quarter of 2025 or the first quarter of 2026.

William Blair served as financial advisor, with Latham & Watkins and Meitar Law Offices providing legal counsel to Sapiens. Citi acted as financial advisor to Advent, while Kirkland & Ellis and Herzog Fox Neeman served as its legal counsel.

Advent is acquiring Sapiens at 24.62 times its EBITDA.

Deal Metrics:

For more in-depth details about this merger and acquisition, please visit the Deal Metrics page here:

Deal Metrics for the acquisition of Sapiens International Corporation N.V. (SPNS) by Advent

The Deal Metrics page for each merger or acquisition includes the following:

  • A spread history chart of the deal from announcement to completion or failure.
  • Every progression event such as the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
  • News and SEC filings.
  • A history of deal updates.
  • And many more details.

Disclaimer: Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article